Amgen said its recent studies found that patients who were given a prescription for a PCSK9 inhibitor to lower cholesterol levels had their insurance claims for the drugs initially turned down by payers.
Based on data from an international clinical trial, U.S. drugmaker Amgen has petitioned the Food and Drug Administration to allow use of Xgeva (denosumab) to prevent bone fractures among multiple myeloma patients.
Amgen said results were positive from the Phase III '482 clinical trial that evaluated Xgeva (denosumab) versus zoledronic acid in preventing fractures and other skeletal-related issues in patients with multiple myeloma.
Amgen said results were positive in a Phase II clinical trial evaluating Imlygic (talimogene laherparepvec) in combination with Yervoy (ipilimumab) in treating unresectable stage IIIb-IV melanoma versus treatment with Yervoy alone.
Amgen researchers said that, based on recent Phase 3 clinical data, its Repatha is an improvement over statin drugs, a class of medicines credited with reducing death by heart disease in a generation of patients.
Patients suffering from multiple myeloma, a cancer of the blood cells, may soon get a new treatment option if officials from the U.S. Food and Drug Administration and the European Medicines Agency expand XGEVA to treat the illness.
The U.S. FDA has accepted Amgen’s supplemental Biologics License Application (sBLA) for BLINCYTO (blinatumomab) to include overall survival data from the Phase 3 TOWER study, Amgen said in a press release.
The life expectancy of leukemia patients may be nearly doubled by the use of Amgen’s new immunotherapy drug, according the results of a clinical trial published March 1 in the New England Journal of Medicine.
Amgen has announced a phase-three study analyzing how XGEVA competes with zoledronic acid when it comes to meeting the primary endpoint of non-inferiority in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma.
Amgen recently announced that its research has revealed new data for Imlygic (talimogene laherparepvec) to treat melanoma and metastatic colorectal cancer, stating that the information will be presented at the European Society for Medical Oncology 2016 Congress.